Case study: Life sciences
Global pharmaceutical company scales adverse event detection on social media
Challenge
Many pharma companies embrace social media for its direct-to-consumer engagement. But that engagement can come at a cost to compliance and ultimately the brand’s reputation. The volume and velocity of digital chatter online can quickly overwhelm compliance teams beholden to industry regulations.
One of the world’s premier biopharmaceutical companies recognized the value of social media early on as a way to strengthen consumer engagement. But building safe online communities required formalizing its global compliance policy to keep pace with its growing online presence.
Regional demand for social media pages grew fast. This rising social media engagement translated to inconsistent moderation, ad-hoc reporting and quality control issues, which inundated compliance teams. It also left the company open to adverse events slipping through the cracks. As the pharma company’s brand strength continued to grow, having a safe and compliant global social media presence was critical.
“The standards and processes implemented with Crisp have enabled our regions to fully embrace social media with confidence.“
Solution
The company engaged Crisp to develop an enterprise-wide social media compliance solution that could scale across owned regional and drug-specific social media pages. Working with global social strategy, central pharmacovigilance and customer engagement teams, Crisp provided social media moderation and best-in-class adverse event detection.
Using its Pharmaceutical Social Compliance solution, Crisp expanded the company’s adverse event protocols and eliminated harmful content. With 24/7/365 coverage across many countries and languages, Crisp ensured compliance via implementation of clear and consistent policies for global moderation, regional onboarding, rollout and transition, and a new quality assurance template.
Accuracy is everything with pharma compliance. Crisp detected and removed harmful content within 15 minutes. Escalation of adverse events and product safety concerns occurred within a 12-24 hour window, giving the pharmaceutical company ample time to meet FDA/EMA regulations. Crisp added further precision with a triple-check process in multiple languages, including human review by native speakers.
Outcome
Crisp delivered far beyond the brand’s expectations and historical benchmarks. Its marketing teams feel more confident than ever and compliance teams have peace of mind, knowing Crisp’s solution is in place.
The partnership with Crisp also benefits the pharma company’s bottom line. With an enterprise-level agreement, the company has realized cost and operational efficiencies. Eliminating local agreements streamlined oversight and ensuring consistent, scalable compliance around the world. Crisp best practices continue to inform the company’s adverse event protocols and training on an ongoing basis.
In addition, perhaps the greatest testament to the partnership’s success is the eagerness of the company’s new regional teams to engage consumers on social media. Despite the volume of comments peaking at multiple points over the last two years, Crisp’s no-miss guarantee gives the company and its regional teams the ability to quickly set up and safely scale new social media pages.
Is your life sciences brand safe and compliant?
Our Blog
Latest perspective and curated insights
Growing social media uncertainty increases risks to brand reputation
Activism a growing risk to fashion brand reputation
Pharma communicators predict more crises on the horizon
How online harms will evolve in the metaverse—and what to do about it
